
Cheng-Ling Lee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6555013/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Increased apoptosis and suburothelial inflammation in patients with ketamineâ€related cystitis: a comparison with nonâ€ulcerative interstitial cystitis and controls. BJU International, 2013, 112, 1156-1162.	1.3	70
2	Intravesical botulinum toxin a injections do not benefit patients with ulcer type interstitial cystitis. Pain Physician, 2013, 16, 109-16.	0.3	47
3	Electron microscopic characteristics of interstitial cystitis/bladder pain syndrome and their association with clinical condition. PLoS ONE, 2018, 13, e0198816.	1.1	34
4	Pathophysiology of benign prostate enlargement and lower urinary tract symptoms: Current concepts. Tzu Chi Medical Journal, 2017, 29, 79.	0.4	33
5	Repeated intravesical injections of platelet-rich plasma improve symptoms and alter urinary functional proteins in patients with refractory interstitial cystitis. Scientific Reports, 2020, 10, 15218.	1.6	30
6	Long-Term Efficacy and Safety of Repeated Intravescial OnabotulinumtoxinA Injections Plus Hydrodistention in the Treatment of Interstitial Cystitis/Bladder Pain Syndrome. Toxins, 2015, 7, 4283-4293.	1.5	28
7	Urothelial Dysfunction, Suburothelial Inflammation and Altered Sensory Protein Expression in Men with Bladder Outlet Obstruction and Various Bladder Dysfunctions: Correlation with Urodynamics. Journal of Urology, 2016, 196, 831-837.	0.2	25
8	Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection in Patients with Detrusor Hyperactivity and Impaired Contractility. Toxins, 2016, 8, 82.	1.5	24
9	Long-term follow up and predictive factors for successful outcome of transurethral incision of the bladder neck in women with detrusor underactivity. Journal of the Formosan Medical Association, 2016, 115, 807-813.	0.8	18
10	Histopathological characteristics of ketamineâ€associated uropathy and their clinical association. Neurourology and Urodynamics, 2018, 37, 1764-1772.	0.8	16
11	Comparative study of efficacy and safety between bladder body and trigonal intravesical onabotulinumtoxina injection in the treatment of interstitial cystitis refractory to conventional treatment—A prospective, randomized, clinical trial. Neurourology and Urodynamics, 2018, 37, 1467-1473.	0.8	13
12	Change of Detrusor Contractility in Patients with and without Bladder Outlet Obstruction at Ten or More Years of follow-up. Scientific Reports, 2019, 9, 18887.	1.6	12
13	Efficacy and safety of mirabegron, a l² ₃ â€adrenoceptor agonist, in patients with detrusor hyperactivity and impaired contractility. LUTS: Lower Urinary Tract Symptoms, 2019, 11, O93-O97.	0.6	10
14	Female bladder neck dysfunction— A video â€urodynamic diagnosis among women with voiding dysfunction. LUTS: Lower Urinary Tract Symptoms, 2020, 12, 278-284.	0.6	10
15	Changes in sensory proteins in the bladder urothelium of patients with chronic kidney disease and endâ€stage renal disease. LUTS: Lower Urinary Tract Symptoms, 2019, 11, O202-O208.	0.6	8
16	Current consensus and controversy on the diagnosis of male lower urinary tract symptoms/benign prostatic hyperplasia. Tzu Chi Medical Journal, 2017, 29, 6.	0.4	8
17	Current pharmacological and surgical treatment of underactive bladder. Tzu Chi Medical Journal, 2017, 29, 187.	0.4	7
18	Real-World Data Regarding Satisfaction to Botulinum Toxin A Injection into the Urethral Sphincter and Further Bladder Management for Voiding Dysfunction among Patients with Spinal Cord Injury and Voiding Dysfunction. Toxins, 2022, 14, 30.	1.5	6

CHENG-LING LEE

#	Article	IF	CITATIONS
19	Tailoring Medication for Lower Urinary Tract Symptoms in Men Based on International Prostate Symptom Score Voiding to Storage Ratio. Urology, 2018, 120, 30-35.	0.5	5
20	Effect of videourodynamic subtypes on treatment outcomes of female dysfunctional voiding. International Urogynecology Journal, 2022, 33, 1283-1291.	0.7	5
21	Adding mirabegron after intravesical <scp>onabotulinumtoxinA</scp> injection improves therapeutic effects in patients with refractory overactive bladder. LUTS: Lower Urinary Tract Symptoms, 2021, 13, 440-447.	0.6	3
22	Therapeutic Effects of Urethral Sphincter Botulinum Toxin A Injection on Dysfunctional Voiding with Different Videourodynamic Characteristics in Non-Neurogenic Women. Toxins, 2021, 13, 362.	1.5	3
23	Male patients with a higher frequency of nocturnal urinary episodes are more likely to benefit from alphaâ€blocker therapy for bothersome nocturia. LUTS: Lower Urinary Tract Symptoms, 2019, 11, 0174-0179.	0.6	1
24	Therapeutic efficacy of mirabegron 25 mg monotherapy in patients with nocturia-predominant hypersensitive bladder. Tzu Chi Medical Journal, 2020, 32, 30.	0.4	1